Samsung Bioepis and Organon shared that the Food and Drug Administration has designated the Hadlima (adalimumab-bwwd) high- ...

Humira brought in over $21 billion ... many of which are summarized in the chart below: Self-Administration: Adalimumab biosimilars are self-administered, joining insulin biosimilars as the ...

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

Biosimilars generally cost less than brand-name drugs. Cimzia and Humira are both given by subcutaneous ... The following chart shows the disease or condition, the study or review of studies ...

Boehringer Ingelheim will sell an unbranded version AbbVie’s reference drug at a 92% discount to gain traction in the Humira (adalimumab) biosimilar market. Patients will be able to purchase ...

Humira, which lists for almost $7,000 a month, is the first top-selling drug to compete with a slew of biosimilars, which are close but not exact copies of branded biologic medicines. Sign up here.

European regulators are to review Sandoz's biosimilars of the inflammatory diseases medicines, Humira and Remicade, as competition intensifies to take market share from big-selling monoclonal anti ...

MedImpact Healthcare Systems, an independent provider of health solutions, technology and pharmacy benefit services, is expanding access to Humira biosimilars, Simlandi and adalimumab-adaz ...

These included about 60 plans that paid only for biosimilars, excluding Humira, which covered 2.1% of Part D enrollees. Moreover, most of the biosimilars with substantial coverage came with a ...

CVS Caremark took Humira off its formularies in April. “With this latest update, we’re prepared to embrace the savings biosimilars offer and pave the way for access to the next wave of ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

With approvals in rheumatoid arthritis, psoriasis, and Crohn's disease, Humira holds a wide range of indications, but biosimilar pressure will likely lead to declining sales over the next few ...